Travere Therapeutics (TVTX) investor relations material

Strategic priorities and performance

• Achieved record patient reach for FILSPARI in IgA nephropathy, with 908 new patient start forms in Q4 and 143% revenue growth projected for 2025 over 2024.

• Ended the year with $410 million in net revenue and $323 million in cash, supporting all three core priorities.

• FDA review of sNDA for FSGS ongoing, with responses to information requests submitted and high-level engagement with the agency.

• Reinitiating the phase III HARMONY study for pegtibatinase in homocystinuria this quarter.

FILSPARI in IgA nephropathy

• FILSPARI demonstrated superior proteinuria reduction and eGFR benefit over RAS inhibition in the PROTECT phase III trial.

• Achieved over $100 million in quarterly revenue, with 108% growth year-over-year and high patient compliance.

• Recent KDIGO guidelines and REMS updates support earlier and combination use of FILSPARI.

• Less than 10% of the 70,000 addressable patients have been reached, indicating significant growth potential.

FSGS regulatory and clinical update

• FDA requested additional analyses to further characterize clinical benefit; responses submitted, with PDUFA date imminent.

• PARASOL Group's work identified proteinuria reduction as a key endpoint for FSGS, with sparsentan showing 50% reduction versus 32% for irbesartan.

• Achieving proteinuria thresholds (0.3g and 0.7g) correlates with 80-90% reduction in kidney failure risk over eight years.

• Real-world and trial data support sparsentan's potential to reduce kidney failure events in FSGS.